227 related articles for article (PubMed ID: 35242677)
1. The expression of m
Yao Y; Luo L; Xiang G; Xiong J; Ke N; Tan C; Chen Y; Liu X
Gland Surg; 2022 Jan; 11(1):147-165. PubMed ID: 35242677
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
3. LDHA is a prognostic biomarker on the immune response in pancreatic adenocarcinoma and associated with m6A modification.
Tan Z; Liu J; Xu J; Zhang B; Yu X; Wang W; Liang C
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4853-4865. PubMed ID: 36269388
[TBL] [Abstract][Full Text] [Related]
4. The coagulation-related genes for prognosis and tumor microenvironment in pancreatic ductal adenocarcinoma.
Wang D; Cui SP; Chen Q; Ren ZY; Lyu SC; Zhao X; Lang R
BMC Cancer; 2023 Jun; 23(1):601. PubMed ID: 37386391
[TBL] [Abstract][Full Text] [Related]
5. Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment.
Deng X; Sun X; Hu Z; Wu Y; Zhou C; Sun J; Gao X; Huang Y
FASEB J; 2023 Sep; 37(9):e23155. PubMed ID: 37606566
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
Front Immunol; 2021; 12():769425. PubMed ID: 34804059
[TBL] [Abstract][Full Text] [Related]
7. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
Tang R; Liu X; Wang W; Hua J; Xu J; Liang C; Meng Q; Liu J; Zhang B; Yu X; Shi S
Cancer Cell Int; 2021 Apr; 21(1):196. PubMed ID: 33827590
[TBL] [Abstract][Full Text] [Related]
8. Thyroid cancer risk prediction model using m6A RNA methylation regulators: integrated bioinformatics analysis and histological validation.
Zhou W; Lin J; Liu J; Zhang R; Fan A; Xie Q; Hong L; Fan D
Aging (Albany NY); 2023 Feb; 15(3):846-865. PubMed ID: 36791151
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive analysis of m6A regulators and relationship with tumor microenvironment, immunotherapy strategies in colorectal adenocarcinoma.
Ji J; Liu S; Liang Y; Zheng G
BMC Genom Data; 2023 Aug; 24(1):44. PubMed ID: 37568073
[TBL] [Abstract][Full Text] [Related]
10. Identification and Validation of Three PDAC Subtypes and Individualized GSVA Immune Pathway-Related Prognostic Risk Score Formula in Pancreatic Ductal Adenocarcinoma Patients.
Zhang D; Wang M; Peng L; Yang X; Li K; Yin H; Xia C; Cui F; Huang H; Jin Z
J Oncol; 2021; 2021():4986227. PubMed ID: 34987579
[TBL] [Abstract][Full Text] [Related]
11. Characterization of m
Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
Front Immunol; 2021; 12():782551. PubMed ID: 34975871
[TBL] [Abstract][Full Text] [Related]
12. M6A-Related Long Non-Coding RNA Displays Utility in Predicting Prognosis, Portraying the Tumor Immune Microenvironment and Guiding Immunotherapy in Pancreatic Ductal Adenocarcinoma.
Xu G; Ji Y; Wang L; Xu H; Shen C; Ye H; Yang X
Vaccines (Basel); 2023 Feb; 11(3):. PubMed ID: 36992083
[TBL] [Abstract][Full Text] [Related]
13. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
14. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of senescence-associated genes in pancreatic ductal adenocarcinoma.
Zhu ZG; Chen L; Miao DL; Jin Y; Wu Q
Front Genet; 2022; 13():941389. PubMed ID: 36046234
[No Abstract] [Full Text] [Related]
16. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
17. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
Hu Y; Chen Y
Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
[TBL] [Abstract][Full Text] [Related]
18. The immune escape signature predicts the prognosis and immunotherapy sensitivity for pancreatic ductal adenocarcinoma.
Lu H; Zheng LY; Wu LY; Chen J; Xu N; Mi SC
Front Oncol; 2022; 12():978921. PubMed ID: 36147906
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Immune-Related Signatures Related to CD4+ T Cell Infiltration With Gene Co-Expression Network in Pancreatic Adenocarcinoma.
Tan Z; Lei Y; Zhang B; Shi S; Liu J; Yu X; Xu J; Liang C
Front Oncol; 2021; 11():674897. PubMed ID: 34367961
[TBL] [Abstract][Full Text] [Related]
20. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma.
Tang R; Zhang Y; Liang C; Xu J; Meng Q; Hua J; Liu J; Zhang B; Yu X; Shi S
PeerJ; 2020; 8():e9602. PubMed ID: 33062408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
